Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gamunex-C for corneal neovascularization and inflammatory conditions
NCT02042027Phase 1Withdrawn
- Sponsor
- University of Utah
- Start
- Jul 2014
- Primary completion
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of immune globulin in corneal neovascularization (CNV), Corneal graft failure (CGF), anterior segment inflammation and 3 more, sponsored by University of Utah. Primary endpoint: Ability to regress neovascularization. Planned start Jul 2014; status: withdrawn.
02
Drugs
immune globulin
03
Conditions
corneal neovascularization (CNV)Corneal graft failure (CGF)anterior segment inflammationCorneal Meltocular cicatricial pemphigoid (OCP)
Beyond the preview
Go deeper on NCT02042027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02042027.